Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma

Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma

Saved in:
Bibliographic Details
Published in:Haematologica (Roma) Vol. 109; no. 4; pp. 1269 - 1273
Main Authors: Song, Yu-Qin, Zhang, Hui-Lai, Huang, Hui-Qiang, Zhang, Qing-Yuan, Jing, Hong-Mei, Wang, Chao, Wu, Chun, Li, Dong-Hang, Dai, Yu, Humphrey, Kathryn, Zhu, Jun
Format: Journal Article
Language:English
Published: Italy Fondazione Ferrata Storti 01-04-2024
Ferrata Storti Foundation
Subjects:
Antibodies, Bispecific
China
Humans
Letter to the Editor
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - pathology
Lymphoma, Non-Hodgkin
China
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 23
Disclosures
CWa is an employee and holds stock in Roche. CWu is an employee and holds stock in Roche. D-HL is an employee of Roche. YD is an employee of Roche. KH is an employee and holds stock in Roche. All other authors have no conflicts of interest to disclose.
Contributions
Y-QS, CWa, CWu, D-HL, KH, and JZ were involved in conception and design of the study. Y-QS, H-LZ, H-QH, Q-YZ, HM-J, and JZ provided study materials or patients. Y-QS, H-LZ, H-QH, Q-YZ, HM-J, CWa, CWu, D-HL, YD, and JZ participated in collection and assembly of data. Y-QS, H-LZ, H-QH, Q-YZ, HM-J, CWa, CWu, D-HL, YD, KH, and JZ were involved in data analysis and interpretation. All authors were involved in manuscript writing and provided final approval for submission and publication. All authors are accountable for all aspects of the work.
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2023.283802